Pathways to Prevention (P2P) Program

Deborah T. Gold, Ph.D.

Deborah T. Gold, Ph.D.

Professor of Medical Sociology
Departments of Psychiatry and Behavioral Sciences, Sociology, and Psychology and Neuroscience
Duke University Medical Center

Deborah Gold is Professor of Medical Sociology in the Departments of Psychiatry and Behavioral Sciences, Sociology, and Psychology and Neuroscience at Duke University Medical Center, Durham, NC. She is Senior Fellow at the Duke Center for the Study of Aging and Human Development and directs the Postdoctoral Research Training Program in Aging there.   

Dr. Gold received her Ph.D. in Human Development and Social Policy from Northwestern University in 1986. She completed a postdoctoral fellowship in medical sociology and gerontology at the Duke Aging Center and joined the Duke faculty in 1988. Dr. Gold is a fellow of the Gerontological Society of America and a member of the American Society of Bone and Mineral Research, American Sociological Association, and Southern Gerontological Society. She is a member of the International Osteoporosis Foundation’s Working Group on Compliance and Persistence with Medications and an Emeritus Trustee of the National Osteoporosis Foundation and is on the Board of the North Carolina Osteoporosis Foundation.

Dr. Gold’s research deals with the consequences of chronic illnesses in late life, and the majority of her research is focused on osteoporosis. In addition to many publications on the psychosocial consequences of osteoporosis and quality of life, Dr. Gold’s work examines compliance with osteoporosis medications as well. She is examining patient preferences in care and the impact of patient-physician communication in medication-related behaviors. She has published over 100 journal articles, books, and book chapters, most of which are related to osteoporosis and coping with chronic illness in later life.

Dr. Gold disclosed the following conflicts of interest for this workshop:

  • Consultant for Amgen and Eli Lilly & Company
  • Speaker for Amgen and Eli Lilly & Company

Return to the Workshop Agenda

Last updated on